Reviewing Continuous Chromatography Solutions, and the Effect the Number of Process Columns has on Specific Productivity and Binding Capacity (EMEA/AsiaPac)

We address optimal configuration of a multi-column continuous chromatography (MCC) system, with insight into the impact antibody titer has on the number of chromatography columns required to optimize productivity of a MCC process.

Continuous multi-column chromatography (MCC) has been gaining increasing interest as an enabling bioprocessing technique that allows for increases in specific productivity (g/L/hr) and operating binding capacity (g mAb/L sorbent) over traditional batch solutions. With recent advances, users have reported an increase in cost savings stemming from reduced resin volumes, lower buffer consumption, and increased resin usage.

Mark Pagkaliwangan presents, with David Johnson moderating, as they discuss MCC solution advances with processes utilizing two columns or more. They will explore how the total number of columns used in a process can affect performance, and how titer and flowrate can be optimized with more columns for greater efficiency and productivity.

• Results of experimental findings and insights from execution of both the BPOG and USP <665> extractables protocols on multiple single-use components including similarities and differences in extraction profiles
• Details of case studies illustrating how Pall’s growing portfolio of BPOG extractables datasets can be used to help support component qualification and overall toxicological risk assessment for single-use systems

Our team will examine common regulatory challenges and areas of uncertainty in the implementation of continuous bioprocessing, and suggest practical, total solutions.

Many industries have adopted a one-piece flow approach (continuous manufacturing) to leverage the core reductions in inventory, increased operational flexibility, and greater product consistency and quality that it delivers. However, biopharmaceutical manufacturers have been slow to put continuous processing theory into practice due to the highly-regulated nature of the industry.

In this webinar,  Peter Levison, PhD will moderate as Mani Krishnan, PhD and Marc Bisschops, PhD examine the evolution of interest in continuous bioprocessing, the advances being made in today’s market, and how the regulatory authorities are responding. Mani will also offer insight into the technological challenges of implementing continuous bioprocesses, and potential regulatory questions surrounding batch definition, bioburden control, virus clearance, scale-up/down, defect perturbation, design space, etc. He will also propose effective mitigation strategies for a successful transition to continuous bioprocessing.    

• Learn how to efficiently remove HCPs and aggregates during mAb production while protecting mAb integrity
• Learn about a new scalable cation exchange mixed-mode sorbent for high performance capture and impurity removal at moderate conductivities

A review of simplified continuous filtration, particularly for UF/DF, with a look into our exclusive licence to patents in the field of single-pass tangential flow filtration (SPTFF), which enables continuous filtration without recirculation at several stages of a continuous bioprocess. ​​

Single-pass tangential flow filtration (SPTFF) technology from Pall Life Sciences is a versatile concentration approach for biotech, vaccine and plasma industry applications. Patented Cadence™ SPTFF technology offers a total solution for inline volume reduction and/or concentration, in-process dilution/de-salting, high concentration formulations, and processing of fragile molecules, crucially enabling integrated, streamlined and continuous bioprocessing initiatives.

In this webinar, moderator Kevin Marino and presenter Jon Petrone provide an overview of SPTFF technology, including case studies where this novel technology was applied to enhance processes and reduce bottlenecks in production.